Kathryn Beal

Kathryn Beal

Auto-generated profile, based on publicly available information

Kathryn Beal

Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2015 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
AKAna P. Kiess
Ana P. Kiess
JWJedd D. Wolchok
Jedd D. Wolchok
CBChristopher Andrew Barker
Christopher Andrew Barker
MPMichael A. Postow
Michael A. Postow
VTViviane Tabar
Viviane Tabar
KBKathryn Beal
Kathryn Beal

26 August 2015 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
ZKZachary A. Kohutek
Zachary A. Kohutek
YYYoshiya Yamada
Yoshiya Yamada
TCTimothy A. Chan
Timothy A. Chan
CBCameron W. Brennan
Cameron W. Brennan
VTViviane Tabar
Viviane Tabar
KBKathryn Beal
Kathryn Beal

1 January 2014 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
CBCameron Brennan
Cameron Brennan
TYT. Jonathan Yang
T. Jonathan Yang
PHPatrick Hilden
Patrick Hilden
ZZZhigang Zhang
Zhigang Zhang
KCKelvin Chan
Kelvin Chan
KBKathryn Beal
Kathryn Beal

12 May 2006 in Cancer
Verified
Journal Article
Open access
PDF file
KBKathryn Beal
Kathryn Beal
LALaura Allen
Laura Allen
JYJoachim Yahalom
Joachim Yahalom
BACKGROUND: To the authors' knowledge, there is limited information on the preferred treatment and long‐term prognosis of primary bone lymphomas (PBLs). All PBL cases treated at the study center between 1963 and 2003 were analyzed to determine patient, disease, and treatment factors that could affect outcome measured by overall survival (OS), cause‐specific survival (CSS), and freedom‐from‐treatment failure (FFTF).METHODS: A total of 101 patients with PBL diagnosed at the study institution were identified. Nineteen patients were excluded because they transferred their treatment or follow‐up to another center. Disease control, survival, and prognostic factors were analyzed for all 82 remaining patients.RESULTS: The median age of the patients was 48 years (range, 11–83 years). Approximately 80% presented with diffuse large‐cell lymphoma (DLCL), and 81% presented with Ann Arbor Stage I or II disease. Approximately 57% were treated with combined modality therapy, 14% were treated with radiation therapy alone, and 30% were treated with chemotherapy alone. The median follow‐up was 67 months (range, 2–280 months). The 5‐year OS, CSS, and FFTF were 88%, 96%, and 81%, respectively. The 5‐year OS for patients treated with combined modality versus single‐modality therapy was 95% versus 78% (P = .013), and the 5‐year FFTF for patients treated with combined modality versus single‐modality therapy was 90% versus 67% (P = .025). The 5‐year CSS for patients treated with combined modality versus single‐modality therapy was 95% versus 83% (P = .065). Using a Cox regression for multivariate analysis, age <40 years and use of combined modality therapy were found to be favorable prognostic factors for OS, CSS, and FFTF.CONCLUSIONS: To the authors' knowledge, the current study is the largest series of patients with PBL treated with modern curative modalities. The data demonstrate that primary lymphoma involving the bone has an excellent prognosis. Patients with PBL treated with combined modality versus single modality therapy were found to have a superior outcome, with a significantly better survival. Cancer 2006. © 2006 American Cancer Society.

27 June 2013 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
DBDustin Boothe
Dustin Boothe
RYRobert Young
Robert Young
YYYoshiya Yamada
Yoshiya Yamada
APAlisa Prager
Alisa Prager
TCTimothy Chan
Timothy Chan
KBKathryn Beal
Kathryn Beal
Cerebral radiation necrosis (RN) is a difficult to treat complication of stereotactic radiosurgery (SRS) that can result in progressive neurologic decline. Currently, steroids are the standard of care treatment for brain RN despite their adverse effect profile and limited efficacy. The purpose of this study was to evaluate the treatment efficacy of cerebral RN to bevacizumab in patients with brain metastases previously treated with SRS. We retrospectively reviewed 14 lesions in 11 patients treated with bevacizumab for brain RN secondary to SRS for their brain metastases. Steroid dosing, RN-associated symptoms, and magnetic resonance imaging (MRI) scans were examined before, during, and after bevacizumab administration. Of the 11 patients included, 6 had metastatic non–small cell lung cancer, and 5 had metastatic breast cancer. The mean percentage decrease in RN volume seen on T1 post-Gadolinium and fluid-attenuated inversion recovery (FLAIR) MRI at first follow-up, at a mean of 26 days (range, 15–43 days), was 64.4% and 64.3%, respectively. MRI changes were sustained on follow-up MRI scans, obtained at a mean of 33 days (range, 7–58 days) after bevacizumab discontinuation. After bevacizumab treatment, all patients initially receiving steroids had a reduction in steroid requirement, and all but one had an improvement in or stability of RN-associated symptoms. No patients experienced intratumoral bleeds or other adverse effects related to their bevacizumab treatment. Bevacizumab is effective and safe for the treatment of RN after SRS for brain metastasis. In this context, bevacizumab offers symptomatic relief, a reduction in steroid requirement, and a dramatic radiographic response.